Portal de Periódicos da CAPES

O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate

2017; Cell Press; Volume: 32; Issue: 2 Linguagem: Inglês

10.1016/j.ccell.2017.07.008

1878-3686

Joshua D. Schoenfeld, Zita A. Sibenaller, Kranti A. Mapuskar, Brett A. Wagner, Kimberly Cramer-Morales, Muhammad Furqan, Sonia Sandhu, Thomas Carlisle, Mark C. Smith, Taher Abu Hejleh, Daniel Berg, Jun Zhang, John Keech, Kalpaj R. Parekh, Sudershan K. Bhatia, Varun Monga, Kellie L. Bodeker, Logan Ahmann, Sandy Vollstedt, Heather A. Brown, Erin P. Shanahan Kauffman, Mary E. Schall, R.J. Hohl, Gerald H. Clamon, Jeremy D.W. Greenlee, Matthew A. Howard, Michael K. Schultz, Bruce A. Smith, Dennis P. Riley, Frederick E. Domann, Joseph J. Cullen, Garry R. Buettner, John M. Buatti, Douglas R. Spitz, Bryan G. Allen,

Nanoparticles: synthesis and applications

(Cancer Cell 31, 487–500; April 10, 2017) In the originally published version of this article, Dr. Michael K. Schultz’s name was mistakenly spelled Michael K. Shultz. The authors regret this error and apologize for any confusion that it may have caused. This has now been corrected here and in the online version of the article. O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological AscorbateSchoenfeld et al.Cancer CellMarch 30, 2017In BriefSchoenfeld et al. show that cancer cells are selectively sensitive to ascorbate due to their altered redox-active iron metabolism. They present preclinical and clinical data demonstrating the feasibility, tolerability, and potential efficacy of pharmacological ascorbate for treating glioblastoma and non-small cell lung cancer. Full-Text PDF Open Archive